MARKET WIREYahoo! Finance Canada • 13h ago
Penumbra, Inc. (PEN) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
Why PEN Stock slipped -0.94% Today — RQD Quant Desk Flash
$318.95 -0.94% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $317.80
Penumbra Inc. (PEN) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $12.68B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Penumbra Inc. (NYSE: PEN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $318.95 (-0.94% 1D, market cap $12.68B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, PEN ranks #207 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PEN compare to BAX and SOLV in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PEN carries a Roarable D+ (57/100 RQD), trailing P/E of 71.4x, gross margin of 67.1%, and ROIC of 10.6%. By comparison, BAX (Baxter International Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B) and SOLV (Solventum Corporation) posts a D grade (45/100 RQD, P/E 9.1x, ROIC 18.7%, cap $14.22B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while SOLV leads on capital efficiency (18.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PEN?
▼
Per PEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001321732), Penumbra Inc. generated $1.40B in revenue (+17.5% YoY), $177.7M in net income, and $174.9M in free cash flow against $1.83B in total assets and $179.5M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $317.80 (-0.36%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 12.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-0.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PEN)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY PEN SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (26% of score)
Altman Z-Score 21.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($174.9M FCF) & 67.1% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)
Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$320.01+1.4% Next Q
65
Q2 (-2Q)Grade C+$324.34-0.1% Next Q
62
Q3 (-1Q)Grade C$324.04-1.6% Next Q
60
CurrentGrade D+$318.95-0.2% Hist 90D α
57
Trajectory: C+ (65) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the PEN Bull Thesis Could Fail
Even with a 57/100 (D+) score, PEN faces multiple-compression risk if 71.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($320.40) or 200D SMA ($327.20) invalidates the momentum regime and cuts Target Base ($317.51) toward Bear Floor ($247.66).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PEN Stock slipped -0.94% Today — RQD Quant Desk Flash
Penumbra Inc. (PEN) slipped -0.94% to $318.95, trading at 69% of its 52-week range ($221.26 – $362.41). Stretched risk/reward at 71x P/E (11% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 69% of its 52-week range ($221.26 – $362.41) with RSI-14 at 51.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±1.8% around $318.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 67.1% gross margin and $174.9M annual free cash flow.
Live PEN Headlines & Catalysts
MARKET WIREYahoo Finance • 16h ago
Penumbra (PEN) Stock Faces Q3 Earnings Valuation ScrutinyYahoo Finance report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 19h ago
Can Penumbra (PEN) Justify Its Valuation As STORM PE Data Strengthens Its Recovery Story?Simply Wall St report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 22h ago
Revenue rose 15.6% at Penumbra (PEN), but quarterly profit went the other way.Stock Titan report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Penumbra (PEN) Clinical Data Puts Its Valuation Back In FocusYahoo Finance report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Penumbra (PEN) Reports Q3 Growth And FDA Clearance, Is The Upside Already Priced In?Simply Wall St report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
Revenue rises 15.6% at Penumbra (PEN), but quarterly profit falls.Stock Titan report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 1d ago
MarketBeat cites USD 367.07 target for Penumbra stockad-hoc-news.de report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREFintel • 3d ago
Penumbra, Inc. Reports Third Quarter 2026 Revenue of $410.1 millionCATALYSTYahoo • 4d ago
Penumbra: Q3 Earnings Snapshot(PEN) on Thursday reported earnings of $42.On a per-share basis, the Alameda, California-based company said it had profit of $1.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PEN)
- ✓Walkthrough of PEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.76%📐 HORIZONTAL RANGE
2026-11-02O $318.3H $322.0L $318.3C $319.0VOL 672.9K
RES: $325.2SUP: $316.4SMA50: $320.4SMA200: $327.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
46.4%/yr Implied 5Y Growth
vs. +17.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PEN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PEN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PEN)
Health Care Rank #207 of 1016
⚔️ BAX vs PEN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PEN vs. BAX, SOLV, GKOS, GMED)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Penumbra Inc. (PEN) ranks #207 by composite RQD confidence (57/100, grade D+) and #90 by equity capitalization ($12.68B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while SOLV leads on capital efficiency and profitability with 18.7% ROIC and 53.5% gross margin. GMED currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PEN at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PEN
ACTIVE
Penumbra Inc. | D+ | 57/100 | 71.4x | 67.1% | 10.6% | -0.94% | $12.68B | Benchmark Subject |
| BAX Baxter International Inc. | D | 51/100 | — | 30.1% | -2.4% | -2.13% | $12.15B | /bax-vs-pen → |
| SOLV Solventum Corporation | D | 45/100 | 9.1x | 53.5% | 18.7% | -2.67% | $14.22B | /solv-vs-pen → |
| GKOS Glaukos Corporation | D+ | 58/100 | — | 55.7% | -13.7% | -2.01% | $14.35B | /gkos-vs-pen → |
| GMED Globus Medical Inc. | B | 72/100 | 20.7x | 67.4% | 8.7% | -5.86% | $11.13B | /gmed-vs-pen → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001321732In its most recent audited fiscal period (FY2025, filed 2025-12-31), Penumbra Inc. (PEN) reported GAAP revenue of $1.40B (+17.5% vs. FY2024 revenue of $1.19B , and +32.6% cumulative change since FY2023) , GAAP net income of $177.7M, operating cash flow of $238.7M, and free cash flow of $174.9M (+18.8% YoY). On the balance sheet, PEN closed FY2025 with $1.83B in total assets against $179.5M in total debt (Altman Z-Score: 21.05, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.40B | $177.7M | $238.7M | $174.9M | $1.83B | $179.5M |
| FY2024 (FY) | 2024-12-31 | $1.19B | $14.0M | $168.5M | $147.3M | $1.53B | $172.0M |
| FY2023 (FY) | 2023-12-31 | $1.06B | $91.0M | $97.3M | $49.7M | $6.98B | $1.63B |
3. PEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Penumbra Inc. (NYSE: PEN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $318.95 (-0.94% 1D, market cap $12.68B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, PEN ranks #207 in composite RQD confidence.
How does PEN compare to BAX and SOLV in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PEN carries a Roarable D+ (57/100 RQD), trailing P/E of 71.4x, gross margin of 67.1%, and ROIC of 10.6%. By comparison, BAX (Baxter International Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B) and SOLV (Solventum Corporation) posts a D grade (45/100 RQD, P/E 9.1x, ROIC 18.7%, cap $14.22B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while SOLV leads on capital efficiency (18.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PEN?
Per PEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001321732), Penumbra Inc. generated $1.40B in revenue (+17.5% YoY), $177.7M in net income, and $174.9M in free cash flow against $1.83B in total assets and $179.5M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PEN trading relative to its 50-day, 200-day, and 52-week technical levels?
PEN last traded at $318.95 (-0.94% on volume of 497,832 shares), positioning the stock -0.45% below its 50-day simple moving average ($320.40) and -2.52% below its 200-day simple moving average ($327.20). Across its 52-week range of $221.26 to $362.41, PEN sits at the 69.2% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($313.21 to $324.69).
PEN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PEN stock moving today?
Why PEN Stock slipped -0.94% Today — RQD Quant Desk Flash. Stretched risk/reward at 71x P/E (11% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 57/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PEN — Penumbra Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:25Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PEN carries an RQD score of 57, a letter grade of D+, and the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:
- Fundamental Cash Engine: 13 / 20 (ROIC 10.6%; FCF yield 1.38%). Returns on capital are present, but the free-cash-flow yield of 1.38% is thin relative to the $12.68B market cap, meaning a prospective investor is paying a high price for each dollar of cash generated.
- Whale 13F Flow: 11 / 20 (institutional accumulation and options positioning). This pillar is below midpoint, indicating institutional positioning provides only modest support in the source data.
- Insider Conviction: 8 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the weakest pillar, signaling limited insider or political-disclosure conviction behind the stock.
- Macro Regime Fit: 10 / 20 (Beta 0.91; sector sensitivity). A beta below 1.0 suggests lower-than-market price sensitivity, but the score reflects limited regime-fit benefit.
- Forensic Balance Sheet: 15 / 20 (Altman Z 21.05; Piotroski F 9/9; Debt/Equity 0.12). This is the strongest pillar: the forensic metrics point to a financially sound balance sheet and clean accounting signals.
Investor implications: the rating's upside driver is the balance-sheet strength and high-quality forensic profile. The valuation tradeoff is significant: the market data shows a P/E (TTM) of 71.4, forward P/E of 60, and EV/EBITDA of 52, which leaves limited margin for error if growth or cash generation disappoints. The low FCF yield (1.38%) and weak insider and institutional conviction scores reinforce the rating's caution. Taken together, the source data describes a financially sturdy company priced richly, with weak conviction signals, which is why the framework's verdict leans toward trimming rather than accumulating.
Snapshot
Business
Penumbra Inc. (PEN) is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, per the company profile. Beyond its sector and industry classification, the source data does not describe its products, customers, or revenue model. Not available in source data for detailed product and customer description. The company's reported revenue, gross margin of 67.1%, and operating margin of 13.5% are presented in the sections below.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1403.7M | $189.2M | $177.7M | N/A | $174.9M | $186.9M | $179.5M |
| FY 2024 | $1194.6M | $9.3M | $14.0M | N/A | $147.3M | $324.4M | $172.0M |
| FY 2023 | $1058.5M | $73.6M | $91.0M | N/A | $49.7M | N/A | $1632.2M |
Per the SEC financials, revenue grew from $1058.5M (FY 2023) to $1403.7M (FY 2025), and net income moved from $14.0M in FY 2024 to $177.7M in FY 2025. Per the market data, gross margin is 67.1%, operating margin 13.5%, and net margin 12.7%, with ROIC at 10.6%. Per the Roarable RQD rating, the Altman Z-Score is 21.05, the Piotroski F-Score is 9/9, and Debt/Equity is 0.12. The FY 2023 debt figure of $1632.2M is markedly higher than the FY 2024 and FY 2025 figures, a discontinuity the source data does not explain.
Recent Catalysts & News Wire Analysis
The news wire contains five items, all relating to PEN:
- Market wire (YELLOW): A Yahoo! Finance Canada report covering market action, institutional positioning, and fundamental catalysts.
- Market wire (YELLOW): A Yahoo Finance headline framing PEN's stock as facing "Q3 Earnings Valuation Scrutiny."
- Market wire (YELLOW): A Simply Wall St piece asking whether valuation is justified as "STORM PE" data strengthens the recovery story.
- Market wire (YELLOW): A Stock Titan report stating revenue rose 15.6% while quarterly profit moved the other way.
- Market wire (YELLOW): A Yahoo Finance headline questioning whether clinical data puts valuation back in focus.
- Catalyst (GREEN): A Simply Wall St piece covering Q3 growth and FDA clearance, asking whether upside is already priced in.
Risk watch items: the valuation-scrutiny headlines and the quarterly profit divergence noted by the Stock Titan report. Proprietary signals: none. Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded.
Open Questions
- What drove the revenue-versus-profit divergence cited in the Stock Titan report, and how does it reconcile with FY 2025 net income of $177.7M?
- Why does reported debt fall from $1632.2M in FY 2023 to $172.0M in FY 2024, and what explains the missing FY 2023 cash figure?
- What products, customers, and revenue streams make up the reported revenue base?
- What specific clinical or FDA events are referenced in the news wire, and what is their expected financial impact?
- What are the current analyst consensus rating and price targets, and how do they compare with the 321.97 price?
PEN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Penumbra Inc. (PEN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 13h ago
Penumbra, Inc. (PEN) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 16h ago
Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny Yahoo Finance report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 19h ago
Can Penumbra (PEN) Justify Its Valuation As STORM PE Data Strengthens Its Recovery Story? Simply Wall St report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 22h ago
Revenue rose 15.6% at Penumbra (PEN), but quarterly profit went the other way. Stock Titan report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus Yahoo Finance report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Penumbra (PEN) Reports Q3 Growth And FDA Clearance, Is The Upside Already Priced In? Simply Wall St report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
Revenue rises 15.6% at Penumbra (PEN), but quarterly profit falls. Stock Titan report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 1d ago
MarketBeat cites USD 367.07 target for Penumbra stock ad-hoc-news.de report covering Penumbra Inc. (PEN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PEN Bull vs. Bear Conversation Board — What's Your Call at $318.95?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PEN 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $347.73 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PEN (D+ • RQD 57/100) a Buy at $321.97?
Welcome to the PEN (Penumbra Inc.) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (71.4x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $247.92 (-23.0%)
Spot @ $321.97 Pump the brakes on PEN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PEN, but look at what you are paying: 71.4x trailing P/E with 67.1% gross margins. Unless Penumbra Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $405.68 (+26.0%)
Spot @ $321.97 PEN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PEN, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $321.97 (52-wk range $221.26 - $362.41), any beat on forward guidance forces shorts and underweight funds to chase.